Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, 100191, PR China.
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, PR China.
J Ethnopharmacol. 2024 Feb 10;320:117431. doi: 10.1016/j.jep.2023.117431. Epub 2023 Nov 19.
ETHNOPHARMACOLOGICAL RELEVANCE: Shenfu injection (SFI) is a well-known Chinese herbal medicine widely used in the treatment of septic shock in China. AIM OF THE STUDY: To explore the clinical safety and effectiveness of combined application of Shenfu injection in the treatment of septic shock on the basis of routine western medical treatment. MATERIALS AND METHODS: Randomized controlled trials published before February 28, 2022 in patients with septic shock were searched in the Chinese Biomedical Literature Service System (SinoMed), Embase, PubMed, Cochrane Library, WOS, Scopus. Stata 15.0 and R 4.2.2 were used to meta-analyze sequential organ failure assessment (SOFA) score, case fatality rate, mean arterial pressure (MAP), arterial lactate (Lac). Adverse effects were analyzed by description. RESULTS: A total of 904 articles were searched and 56 RCTs were included, with a total of 4279 participants. Among them, there were 2148 cases in the SFI group and 2131 cases in the control group. The meta-analysis showed that, comparing with routine western medical therapy, the combined use of SFI could effectively reduce 24 h SOFA (MD = -0.79, 95%CI: (-1.12) - (-0.46)), 72 h SOFA (MD = -1.53, 95%CI: (-1.89) - (-1.17)) and 7 d SOFA (MD = -1.55; 95%CI: (-2.86) - (-0.24)). Besides, combined use of SFI could reduce 14 d case fatality rate (RR = 0.16, 95% CI: 0.07-0.37) and 28 d case fatality rate (RR = 0.82, 95% CI: 0.71-0.95). While SFI group showed almost the same effect in 7 d case fatality rate as control (RR: 0.76; 95% CI: 0.42-1.37; P = 0.37). SFI could increase 6 h MAP (MD = 6.40, 95% CI: 3.43-9.37) and 24 h MAP (MD = 4.79, 95% CI: 1.62-7.95). Additionally, SFI could decrease 6 h Lac (MD = -0.90, 95% CI: (-1.34) - (-0.45)), 24 h Lac (MD = -0.80, 95% CI: (-1.20) - (-0.40)), 48 h Lac (MD = -0.67, 95% CI: (-1.05) - (-0.29)). CONCLUSIONS: Shenfu injection combined with RWT showed better therapeutic effect than RWT. SFI plus RWT can improve clinical prognosis of patients with septic shock.
目的:在常规西医治疗的基础上,探讨参附注射液联合治疗脓毒性休克的临床安全性和有效性。
材料和方法:检索中国生物医学文献服务系统(SinoMed)、Embase、PubMed、Cochrane Library、WOS、Scopus 数据库,检索截止日期为 2022 年 2 月 28 日。收集关于参附注射液联合常规西医治疗脓毒性休克的随机对照试验。使用 Stata 15.0 和 R 4.2.2 软件进行序贯器官衰竭评估(SOFA)评分、病死率、平均动脉压(MAP)、动脉血乳酸(Lac)的荟萃分析。不良反应采用描述性分析。
结果:共检索到 904 篇文献,纳入 56 项 RCT,共 4279 例患者。其中参附注射液组 2148 例,对照组 2131 例。Meta 分析结果显示,与常规西医治疗相比,参附注射液联合治疗可有效降低 24 h SOFA(MD=-0.79,95%CI:-1.12-0.46)、72 h SOFA(MD=-1.53,95%CI:-1.89-1.17)和 7 d SOFA(MD=-1.55,95%CI:-2.86-0.24)。此外,参附注射液联合治疗可降低 14 d 病死率(RR=0.16,95%CI:0.070.37)和 28 d 病死率(RR=0.82,95%CI:0.710.95)。参附注射液组在 7 d 病死率方面与对照组差异无统计学意义(RR=0.76,95%CI:0.421.37;P=0.37)。参附注射液可升高 6 h MAP(MD=6.40,95%CI:3.439.37)和 24 h MAP(MD=4.79,95%CI:1.627.95)。参附注射液还可降低 6 h Lac(MD=-0.90,95%CI:-1.34-0.45)、24 h Lac(MD=-0.80,95%CI:-1.20-0.40)、48 h Lac(MD=-0.67,95%CI:-1.05~-0.29)。
结论:参附注射液联合 RWT 治疗脓毒性休克的疗效优于 RWT。参附注射液联合 RWT 可改善脓毒性休克患者的临床预后。
Zhongguo Zhong Yao Za Zhi. 2013-9
Medicine (Baltimore). 2020-10-23
J Ethnopharmacol. 2019-1-11